Search

Your search keyword '"Ipilimumab -- Analysis"' showing total 57 results
Start Over Descriptor "Ipilimumab -- Analysis"
57 results on '"Ipilimumab -- Analysis"'

1. Network meta-analysis of pembrolizumab as monotherapy and in combination with chemotherapy for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma/Metanalise em rede comparativa de pembrolizumabe como monoterapia e em combinacao com quimioterapia para tratamento de primeira linha de carcinoma de celulas escamosas da cabeca e pescoco recorrente ou metastatico

Author

Mojebi, Ali, Ramakrishnan, Karthik, Ayers, Dieter, Keeping, Sam, Borse, Rebekah, and Chirovsky, Diana

Published
2024
Full Text
View/download PDF

2. A Population-Based Study of Patients With Small Cell Carcinoma of the Ovary, Hypercalcemic Type, Encompassing a 30-Year Period

Author

Blatnik, Ana, Dragos, Vita Setrajcic, Blatnik, Olga, Stegel, Vida, Klancar, Gasper, Novakovic, Srdjan, Drev, Primoz, Zagar, Tina, Merlo, Sebastjan, Skof, Erik, Bojadziski, Mirjana Pavlova, Strojnik, Ksenija, and Krajc, Mateja

Subjects
Medical research -- Analysis, Medicine, Experimental -- Analysis, Immunohistochemistry -- Analysis, Ipilimumab -- Analysis, Medical records -- Analysis, Immunotherapy -- Analysis, Ethylenediaminetetraacetic acid -- Analysis, Carcinoma -- Analysis, Cancer -- Analysis, Genetic screening -- Analysis, Health
Abstract

* Context.--Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare and lethal tumor, characterized by hypercalcemia and early onset and associated with germline and somatic SMARCA4 variants. Objective.--To identify all known cases of SCCOHT in the Slovenian population from 1991 to 2021 and present genetic testing results, histopathologic findings, and clinical data for these patients. We also estimate the incidence of SCCOHT. Design.--We conducted a retrospective analysis of hospital medical records and data from the Slovenian Cancer Registry in order to identify cases of SCCOHT and obtain relevant clinical data. Histopathologic review of tumor samples with assessment of immunohistochemical staining for SMARCA4/BRG1 was undertaken to confirm the diagnosis of SCCOHT. Germline and somatic genetic analyses were performed using targeted next-generation sequencing. Results.--Between 1991 and 2021, we identified 7 cases of SCCOHT in a population of 2 million. Genetic causes were determined in all cases. Two novel germline loss-of-function variants in SMARCA4 LRG_878t1:c.1423_1429delTACCTCA p.(Tyr475Ilefs*24) and LRG_878t1: c.3216-1G>T were identified. At diagnosis, patients were ages 21 to 41 and had International Federation of Gynecology and Obstetrics, or FIGO, stage IA-III disease. Outcomes were poor, with 6 of 7 patients dying of disease-related complications within 27 months from diagnosis. One patient had stable disease for 12 months while receiving immunotherapy. Conclusions.--We present genetic, histopathologic, and clinical characteristics for all cases of SCCOHT identified in the Slovenian population during a 30-year period. We report 2 novel germline SMARCA4 variants, possibly associated with high penetrance. We estimate the minimal incidence of SCCOHT to be 0.12 per 1 million per year., Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a very rare and devastatingly lethal tumor, first defined by Scully (1) in 1979 and described in more detail by [...]

Published
2024
Full Text
View/download PDF

3. Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade

Author

Hayashi, Hidetoshi, Chamoto, Kenji, Hatae, Ryusuke, Kurosaki, Takashi, Togashi, Yosuke, Fukuoka, Kazuya, Goto, Megumi, Chiba, Yasutaka, Tomida, Shuta, Ota, Takayo, Haratani, Koji, Takahama, Takayuki, Tanizaki, Junko, Yoshida, Takeshi, Iwasa, Tsutomu, Tanaka, Kaoru, Takeda, Masayuki, Hirano, Tomoko, Yoshida, Hironori, Ozasa, Hiroaki, Sakamori, Yuichi, Sakai, Kazuko, Higuchi, Keiko, Uga, Hitoshi, Suminaka, Chihiro, Hirai, Toyohiro, Nishio, Kazuto, Nakagawa, Kazuhiko, and Honjo, Tasuku

Subjects
Medical research -- Analysis, Medicine, Experimental -- Analysis, Tumors -- Care and treatment, Gene expression -- Analysis, T cells -- Analysis, Ipilimumab -- Analysis, Immune response -- Analysis, B cells -- Analysis, Chemotherapy -- Analysis, Lung cancer, Non-small cell -- Care and treatment, Cancer -- Chemotherapy, Health care industry
Abstract

BACKGROUND. Precise stratification of patients with non-small cell lung cancer (NSCLC) is needed for appropriate application of PD-1/PD-L1 blockade therapy. METHODS. We measured soluble forms of the immune-checkpoint molecules PD-L1, PD-1, and CTLA-4 in plasma of patients with advanced NSCLC before PD-1/PD-L1 blockade. A prospective biomarker-finding trial (cohort A) included 50 previously treated patients who received nivolumab. A retrospective observational study was performed for patients treated with any PD-1/PD-L1 blockade therapy (cohorts B and C), cytotoxic chemotherapy (cohort D), or targeted therapy (cohort E). Plasma samples from all patients were assayed for soluble immune-checkpoint molecules with a highly sensitive chemiluminescence-based assay. RESULTS. Nonresponsiveness to PD-1/PD-L1 blockade therapy was associated with higher concentrations of these soluble immune factors among patients with immune-reactive (hot) tumors. Such an association was not apparent for patients treated with cytotoxic chemotherapy or targeted therapy. Integrative analysis of tumor size, PD-L1 expression in tumor tissue (tPD-L1), and gene expression in tumor tissue and peripheral [CD8.sup.+] T cells revealed that high concentrations of the 3 soluble immune factors were associated with hyper or terminal exhaustion of antitumor immunity. The combination of soluble PD-L1 (sPD-L1) and sCTLA-4 efficiently discriminated responsiveness to PD-1/PD-L1 blockade among patients with immune-reactive tumors. CONCLUSION. Combinations of soluble immune factors might be able to identify patients unlikely to respond to PD- 1/PD-L1 blockade as a result of terminal exhaustion of antitumor immunity. Our data suggest that such a combination better predicts, along with tPD-L1, for the response of patients with NSCLC. TRIAL REGISTRATION. UMIN000019674. FUNDING. This study was funded by Ono Pharmaceutical Co. Ltd. and Sysmex Corporation., Introduction Targeting of the immune system has provided clinical benefit for individuals with advanced solid tumors, including non-small cell lung cancer (NSCLC) (1). Currently approved immune-checkpoint inhibitors (ICIs) include monoclonal [...]

Published
2024
Full Text
View/download PDF

4. Researcher from National Cancer Institute (NCI) Details Findings in Squamous Cell Carcinoma (Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary ...)

Subjects
United States. National Cancer Institute -- Analysis, Oncology, Experimental -- Analysis, Biochemistry -- Analysis, Ipilimumab -- Analysis, Immunotherapy -- Analysis, Squamous cell carcinoma -- Analysis, Clinical trials -- Analysis, Cancer -- Research, Health
Abstract

2024 JUL 24 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators publish new report on squamous cell carcinoma. According to news reporting from Bethesda, Maryland, [...]

Published
2024

5. Radiomic analysis of patient and inter-organ heterogeneity in response to immunotherapies and BRAF targeted therapy in metastatic melanoma

Subjects
Ipilimumab -- Analysis, Cancer patients -- Care and treatment, Metastasis -- Care and treatment, Immunotherapy -- Analysis, Cancer -- Care and treatment, Medical imaging equipment -- Analysis, Melanoma -- Care and treatment, Health
Abstract

2024 MAY 15 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- According to news reporting based on a preprint abstract, our journalists obtained the following quote [...]

Published
2024

7. Study Findings on Carcinomas Described by Researchers at Yale University Cancer Center [Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN ...]

Subjects
Oncology, Experimental -- Analysis, Ipilimumab -- Analysis, Immunotherapy -- Analysis, Cancer -- Care and treatment -- Research, Carcinoma, Renal cell -- Care and treatment, Health
Abstract

2024 MAY 1 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Current study results on carcinomas have been published. According to news reporting from New Haven, [...]

Published
2024

8. A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target

Author

Freeman, Zachary T., Nirschl, Thomas R., Hovelson, Daniel H., Johnston, Robert J., Selby, John J. EngelhardMark J., Kochel, Christina M., Lan, Ruth Y., Zhai, Jingyi, Ghasemzadeh, Ali, Gupta, Anuj, Skais, Alyza M., Wheelan, Sarah J., Jiang, Hui, Pearson, Alexander T., Snyder, Linda A., Korman, Alan J., Tomlins, Scott A., Yegnasubramanian, Srinivasan, and Drake, Charles G.

Subjects
Thermo Fisher Scientific Inc., Janssen Inc., Cancer treatment -- Analysis, Ipilimumab -- Analysis, Apoptosis -- Analysis, Cancer -- Analysis, RNA sequencing -- Analysis, Immunotherapy -- Analysis, Antibodies -- Analysis, Pharmaceutical industry -- Analysis, Immune response -- Analysis, Genomics -- Analysis, Scientific equipment industry -- Analysis, T cells -- Analysis, Biochemistry, Lymphocytes, Tumors, Cell death, Genomes, RNA, Health care industry
Abstract

Despite advancements in targeting the immune checkpoints program cell death protein 1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) for cancer immunotherapy, a large number of patients and cancer types remain unresponsive. Current immunotherapies focus on modulating an antitumor immune response by directly or indirectly expanding antitumor CD8 T cells. A complementary strategy might involve inhibition of Tregs that otherwise suppress antitumor immune responses. Here, we sought to identify functional immune molecules preferentially expressed on tumor-infiltrating Tregs. Using genome-wide RNA-Seq analysis of purified Tregs sorted from multiple human cancer types, we identified a conserved Treg immune checkpoint signature. Using immunocompetent murine tumor models, we found that antibody-mediated depletion of 4-1BB-expressing cells (4-1BB is also known as TNFRSF9 or CD137) decreased tumor growth without negatively affecting CD8 T cell function. Furthermore, we found that the immune checkpoint 4-1BB had a high selectivity for human tumor Tregs and was associated with worse survival outcomes in patients with multiple tumor types. Thus, antibody-mediated depletion of 4-1BB-expressing Tregs represents a strategy with potential activity across cancer types., Introduction Immune checkpoint molecules are a group of surface proteins expressed on various immune cell subsets that can function as either stimulatory or inhibitory mediators, depending upon cell-specific and contextual [...]

Published
2020
Full Text
View/download PDF

9. Immunotherapy in Advanced Lung Cancer

Author

Huang, Joy and Reckamp, Karen L.

Subjects
Carboplatin -- Analysis, Ipilimumab -- Analysis, Metastasis -- Drug therapy, Immunotherapy -- Analysis, B cells -- Analysis, Lung cancer, Non-small cell -- Drug therapy, Chemotherapy -- Analysis, Cancer -- Chemotherapy, Health
Abstract

Historically, platinum-based chemotherapy was the standard of care for metastatic lung cancer. However, since the success of immune checkpoint inhibitors (ICIs) in melanoma, PD-1/PD-L1 and CTLA-4 immune checkpoint pathways have been established as effective therapies to manage advanced non-small cell lung cancer (NSCLC) and extensive-stage (ES) small cell lung cancer (SCLC). Multiple large-scale randomized clinical trials have analyzed the effects of ICIs in NSCLC, and results of these trials have since translated to the approval of single-agent PD-1/PD-L1 inhibitors, and the combination of PD-1 inhibitors with platinum-based chemotherapy has become the new standard of care for patients with advanced NSCLC. Furthermore, in ES SCLC, in which chemotherapy or chemoradiation has been the standard of care for decades, 2 anti-PD-1/PD-L1 agents have been approved for use in the frontline setting for ES SCLC, in combination with chemotherapy. Despite progressive integration of immunotherapy into treatment regimens, there remains a need for reliable biomarkers to precisely determine therapy candidates., Immune Checkpoint Inhibitors Tumor cells can usurp immune checkpoint signals--CD28/B7 activating signal and CTLA-4 and PD-1/PD-L1 inhibitory signals--to dampen effector T-cell responses to promote tumor cell survival and cancer progression. [...]

Published
2020

10. Tracon Pharmaceuticals announces dosing of 36th patient in ENVASARC trial

Subjects
Ipilimumab -- Analysis, Business, News, opinion and commentary
Abstract

TRACON Pharmaceuticals announced the enrollment of the 36th patient in the ENVASARC pivotal trial at the 600 mg dose of envafolimab, which enables the initial independent data monitoring committee, IDMC, [...]

Published
2022

11. Exelixis announces COSMIC-313 met primary endpoint, missed secondary endpoint

Subjects
Ipilimumab -- Analysis, Business, News, opinion and commentary
Abstract

Exelixis announced that COSMIC-313 met its primary endpoint, demonstrating significant improvement in progression-free survival, or PFS, at the primary analysis. COSMIC-313 is an ongoing phase 3 pivotal trial evaluating the [...]

Published
2022

12. Ultimovacs provides update on Phase II NIPU trial evaluating UV1 in patients with malignant pleural mesothelioma

Subjects
Medical research -- Analysis, Medicine, Experimental -- Analysis, Ipilimumab -- Analysis, Mesothelioma -- Care and treatment, Clinical trials -- Analysis, Vaccines -- Product development, General interest, News, opinion and commentary
Abstract

OSLO: Ultimovacs ASA, a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announced the topline results of NIPU, an investigator-initiated Phase II trial in patients indicated for second-line treatment of [...]

Published
2023

13. Ultimovacs ASA: Ultimovacs provides update on Phase II NIPU trial evaluating UV1 in second-line patients with malignant pleural mesothelioma

Subjects
Medical research -- Analysis, Medicine, Experimental -- Analysis, Ipilimumab -- Analysis, Mesothelioma -- Care and treatment, Clinical trials -- Analysis, Vaccines -- Product development, Business, international
Abstract

Oslo: Ultimovacs ASA has issued the following news release: Ultimovacs ASA ('Ultimovacs') (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, today announced the topline results of NIPU, [...]

Published
2023

14. A multidimensional analysis reveals distinct immune phenotypes and tertiary lymphoid structure-like aggregates in the bone marrow of pediatric acute myeloid leukemia (Updated October 30, 2023)

Subjects
Pediatrics -- Analysis, T cells -- Analysis -- Genetic aspects, Ipilimumab -- Analysis, Immunotherapy -- Analysis, Health
Abstract

2023 NOV 13 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- According to news reporting based on a preprint abstract, our journalists obtained the following quote [...]

Published
2023

15. Reports from IRCCS Ospedale Policlinico San Martino Describe Recent Advances in Oncology (Biopsy-proven acute tubulointerstitial nephritis in patients treated with immune checkpoint inhibitors: a pooled analysis of case reports)

Subjects
Ipilimumab -- Analysis, Cancer patients -- Care and treatment, Nephritis -- Care and treatment, Immunotherapy -- Analysis, Health
Abstract

2023 NOV 8 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators discuss new findings in oncology. According to news reporting out of Genova, Italy, by [...]

Published
2023

16. Findings from Northwestern University Update Knowledge of Lung Cancer (Nivolumab Plus Ipilimumab Vs Nivolumab Alone In Advanced Cancers Other Than Melanoma & Nbsp;a Meta-analysis)

Subjects
EBSCO Information Services, Ipilimumab -- Analysis, Immunotherapy -- Analysis, Information services industry -- Analysis, Lung cancer -- Analysis, Information services -- Analysis, Melanoma -- Analysis, Information services industry, Health, Northwestern University
Abstract

2023 OCT 18 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators discuss new findings in Oncology - Lung Cancer. According to news reporting originating from [...]

Published
2023

17. New Findings from Pathology Unit in the Area of Prostate Cancer Published (What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic-Pathologic Correlations)

Subjects
Medical research -- Analysis, Medicine, Experimental -- Analysis, Prostate cancer -- Analysis, Ipilimumab -- Analysis, Cancer -- Analysis, Physical fitness -- Analysis, Health
Abstract

2021 DEC 18 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on prostate cancer have been published. According to news [...]

Published
2021

18. Instil Bio presents subset analysis of patients from compassionate use study

Subjects
Medical research -- Analysis, Medicine, Experimental -- Analysis, Ipilimumab -- Analysis, Business, News, opinion and commentary
Abstract

Instil Bio announced that a subset analysis of treatment outcomes with unselected autologous tumor infiltrating lymphocytes in patients with checkpoint inhibitor-refractory advanced cutaneous melanoma was presented today at the 2021 [...]

Published
2021

19. iTeos Therapeutics announces new phase 1/2a data on inupadenant

Subjects
Ipilimumab -- Analysis, Clinical trials -- Analysis, Business, News, opinion and commentary
Abstract

iTeos Therapeutics announced new clinical data from its ongoing Phase 1/2a clinical trial of inupadenant, a next-generation adenosine receptor antagonist, at the American Society of Clinical Oncology Annual Meeting 2021. [...]

Published
2021

20. Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo(r) (cemiplimab) in Multiple Solid Tumor Types

Subjects
Regeneron Pharmaceuticals Inc., Tumors -- Analysis, Ipilimumab -- Analysis, Cervical cancer -- Analysis, Lung cancer, Non-small cell -- Analysis, Melanoma -- Analysis, General interest, News, opinion and commentary, Libtayo (Medication)
Abstract

TARRYTOWN: Regeneron Pharmaceuticals, Inc. has issued the following news release: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data across its oncology pipeline will be presented at the [...]

Published
2022

21. Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo (cemiplimab) in Multiple Solid Tumor Types

Subjects
Regeneron Pharmaceuticals Inc., Ipilimumab -- Analysis, Cervical cancer -- Analysis, Lung cancer, Non-small cell -- Analysis, Cancer -- Analysis, Melanoma -- Analysis, Pharmaceutical industry -- Analysis, Business, News, opinion and commentary, Libtayo (Medication)
Abstract

Presentations include initial results for an investigational combination of fianlimab (LAG-3 inhibitor) and Libtayo (PD-1 inhibitor) in advanced non-small cell lung cancer TARRYTOWN, N.Y., Dec. 1, 2022 /PRNewswire/ -- Regeneron [...]

Published
2022

22. Systematic review and network meta-analysis of drug combinations suggested by machine learning on genes and proteins, with the aim of improving the effectiveness of Ipilimumab in treating Melanoma

Subjects
Skin cancer -- Analysis, Genes -- Analysis, Ipilimumab -- Analysis, Drug therapy, Combination -- Analysis, Immunotherapy -- Analysis, Machine learning -- Analysis, Melanoma -- Analysis, Health
Abstract

2023 MAY 31 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- According to news reporting based on a preprint abstract, our journalists obtained the following quote [...]

Published
2023

23. Data from Yale University School of Medicine Update Knowledge in Takotsubo Cardiomyopathy (Takotsubo Cardiomyopathy in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Included Cases)

Subjects
Heart diseases -- Analysis, Cancer patients -- Analysis, Ipilimumab -- Analysis, Immunotherapy -- Analysis, Cancer -- Analysis, Cardiomyopathy -- Analysis, Health
Abstract

2023 MAY 31 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators publish new report on takotsubo cardiomyopathy. According to news originating from New Haven, Connecticut, [...]

Published
2023

24. New Melanoma Data Have Been Reported by Investigators at Nagoya University Hospital (Retrospective Analysis of Neutrophil-to-lymphocyte Ratio In Patients With Melanoma Who Received Ipilimumab Monotherapy or Ipilimumab In Combination With ...)

Subjects
Ipilimumab -- Analysis, Lymphocytes -- Analysis, Immunotherapy -- Analysis, Melanoma -- Prognosis -- Care and treatment, Health
Abstract

2023 APR 19 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Fresh data on Oncology - Melanoma are presented in a new report. According to news [...]

Published
2023

25. New Findings in Pneumonia Described from Central South University (Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: A systematic literature review of published case reports and disproportionality analysis based on ...)

Subjects
Bacterial pneumonia -- Analysis, Ipilimumab -- Analysis, Immunotherapy -- Analysis, Pneumonia -- Analysis, Health
Abstract

2023 MAR 29 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Researchers detail new data in pneumonia. According to news reporting out of Hunan, People's Republic [...]

Published
2023

27. Exelixis announces late-stage Cabometyx combo kidney cancer trial results

Subjects
Exelixis Inc., Ipilimumab -- Analysis, Biotechnology industry -- Analysis, Business, international, Cabometyx (Medication)
Abstract

EXELIXIS INC (NASDAQ:EXEL) released Phase 3 study findings for cabozantinib (Cabometyx), nivolumab, and ipilimumab in advanced RCC patients. Data given at 2022 ESMO Congress. The cabozantinib combination decreased disease progression [...]

Published
2022

29. Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer

Subjects
Exelixis Inc., Ipilimumab -- Analysis, Biotechnology industry -- Analysis, Cancer -- Care and treatment -- Patient outcomes, General interest, News, opinion and commentary
Abstract

ALAMEDA, Calif.: Exelixis, Inc. has issued the following news release: Exelixis, Inc. (Nasdaq: EXEL) today announced that COSMIC-313 met its primary endpoint, demonstrating significant improvement in progression-free survival (PFS) at [...]

Published
2022

30. Investigators from National Cancer Center Hospital East Release New Data on Melanoma (Updated Analysis of Nivolumab and Ipilimumab Combination Therapy In Japanese Patients With Advanced Melanoma)

Subjects
Ipilimumab -- Analysis, Immunotherapy -- Analysis, Cancer -- Care and treatment, Melanoma -- Care and treatment, Health
Abstract

2023 JAN 18 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Data detailed on Oncology - Melanoma have been presented. According to news originating from Chiba, [...]

Published
2023

31. New Findings from National Cancer Institute (NCI) in Carcinomas Provides New Insights (Nivolumab Plus Ipilimumab Plus Cabozantinib Triplet Combination for Patients With Previously Untreated Advanced Renal Cell Carcinoma: Results From a ...)

Subjects
United States. National Cancer Institute -- Analysis, Ipilimumab -- Analysis, Immunotherapy -- Analysis, Carcinoma, Renal cell -- Care and treatment, Health
Abstract

2022 DEC 28 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- New research on Oncology - Carcinomas is the subject of a report. According to news [...]

Published
2022

32. Studies from University Hospital Essen Reveal New Findings on Melanoma [Adjuvant Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Placebo In Patients With Resected Stage Iv Melanoma With No Evidence of Disease (Immuned): Final Results of a ...]

Subjects
Bristol-Myers Squibb Co., Ipilimumab -- Analysis, Immunotherapy -- Analysis, Pharmaceutical industry -- Analysis, Health
Abstract

2022 DEC 7 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators publish new report on Oncology - Melanoma. According to news reporting from Essen, Germany, [...]

Published
2022

33. Study Results from Dana-Farber Cancer Institute Provide New Insights into Obesity (Complex Inter-relationship of Body Mass Index, Gender and Serum Creatinine On Survival: Exploring the Obesity Paradox In Melanoma Patients Treated With ...)

Subjects
Cancer -- Patient outcomes -- Care and treatment -- Analysis, Nivolumab -- Analysis, Ipilimumab -- Analysis, Cancer research -- Analysis, Pembrolizumab -- Analysis, Body mass index -- Analysis, Women's health -- Analysis, Editors, Health, Women's issues/gender studies
Abstract

2019 MAY 16 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators discuss new findings in Nutritional and Metabolic Diseases and Conditions - Obesity. According [...]

Published
2019

34. 'Highest survival' reported with combination immunotherapy

Author

Nelson, Roxanne

Subjects
Ipilimumab -- Analysis, Immunotherapy -- Analysis, Cancer -- Care and treatment, Melanoma -- Care and treatment, Health, Health care industry
Abstract

An updated analysis of the phase 3 CheckMate 067 trial confirms the durability of combination immunotherapy for metastatic melanoma, representing a 'substantial development' in treatment, researchers say. Nearly half the [...]

Published
2022

35. PathAI Composite PD-L1 and AI-powered CD8+ Topology Biomarker May Improve Prediction of Immuno-Oncology Treatment Response in Patients with Melanoma at the Society for Immunotherapy of Cancer Meeting 2021

Subjects
Medical research -- Analysis, Medicine, Experimental -- Analysis, Ipilimumab -- Analysis, Immunotherapy -- Analysis, Cancer -- Care and treatment -- Drug therapy -- Prognosis, Melanoma -- Drug therapy -- Prognosis, General interest, News, opinion and commentary
Abstract

BOSTON: PathAI has issued the following news release: PathAI, a global provider of AI-powered technology applied to pathology announced that results from a recent exploratory biomarker analysis on digitized slides [...]

Published
2021

36. PathAI Composite PD-L1 and AI-powered CD8+ Topology Biomarker May Improve Prediction of Immuno-Oncology Treatment Response in Patients with Melanoma at the Society for Immunotherapy of Cancer Meeting 2021

Subjects
Ipilimumab -- Analysis, Immunotherapy -- Analysis, Cancer -- Care and treatment -- Drug therapy, Melanoma -- Drug therapy, Business, News, opinion and commentary
Abstract

Retrospective analysis of digitized immunohistochemistry-stained tumor biopsies of advanced melanoma patients treated with nivolumab monotherapy or the combination of nivolumab plus ipilimumab collected in a clinical trial revealed a subpopulation [...]

Published
2021

37. Five-year data from CheckMate -214 show Opdivo (nivolumab) plus Yervoy (ipilimumab) demonstrates longest median overall survival currently reported in Phase 3 trial of patients with previously untreated advanced or metastatic renal cell carcinoma

Subjects
Bristol-Myers Squibb Co. -- Product development, Medical research -- Analysis, Medicine, Experimental -- Analysis, Ipilimumab -- Analysis, Metastasis -- Care and treatment -- Prognosis -- Patient outcomes, Carcinoma, Renal cell -- Care and treatment -- Prognosis -- Patient outcomes, Pharmaceutical industry -- Product development, Business, Chemicals, plastics and rubber industries, Yervoy (Medication) -- Product development, Opdivo (Medication) -- Product development
Abstract

Bristol Myers Squibb announced on 16 Sep 2021 that Opdivo (nivolumab) plus Yervoy (ipilimumab) continued to demonstrate durable, long-term survival in the Phase 3 CheckMate -214 trial, with a five-year survival rate of 48% in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC). After a median follow-up of 67.7 months, Opdivo plus Yervoy maintained superior overall survival (OS) and response benefits versus sunitinib in both patients with intermediate- and poor-risk prognostic factors, the primary endpoint population, and across all randomized patients. In intermediate- and poor-risk patients (n=847), Opdivo plus Yervoy (n=425) maintained treatment effects over five years, with ongoing improvements in OS and overall response rate (ORR), two of the trial's primary endpoints, as well as in supportive endpoints: The median OS was 47.0 months for intermediate- and poor-risk patients treated with Opdivo plus Yervoy versus 26.6 months with sunitinib, and five-year survival rates were 43% and 31%, respectively. ORR benefits were maintained with Opdivo plus Yervoy compared to sunitinib (42% vs 27%). In addition, more patients treated with the combination achieved complete responses (11% vs 2%). Duration of response (DOR): For patients treated with Opdivo plus Yervoy, median DOR was not reached, compared to 19.7 months with sunitinib. An analysis of all randomized patients, or the intent-to-treat (ITT) population (n=1096), similarly showed long-term benefits with Opdivo plus Yervoy (n=550). Opdivo plus Yervoy demonstrated a median OS of 55.7 months in the ITT population, representing the longest survival outcome reported to date in a Phase 3 trial in advanced RCC, compared to 38.4 months with sunitinib. Five-year OS rates were 48% for patients treated with the dual immunotherapy combination and 37% for those receiving sunitinib. Opdivo plus Yervoy continued to show a higher ORR (39% vs 32%) and complete response rate than sunitinib (12% vs 3%). Also, more patients treated with the combination achieved complete responses and subsequently did not progress (9.6% vs 2.4%). DOR: Median DOR was not reached with Opdivo plus Yervoy and was 24.8 months with sunitinib. The safety profile of Opdivo plus Yervoy was manageable using established treatment algorithms, and no new safety signals emerged with extended follow-up. These data were published online during the European Society for Medical Oncology (ESMO) Virtual Congress 2021 on 16 Sep 2021. The five-year data from CheckMate -214 presented during ESMO also included conditional survival analyses, which estimate the probability of remaining event-free (ie, remaining alive, progression-free or in response) for a period of time after a patient reaches a milestone in their treatment. Key findings included: Patients who were alive three years after starting treatment with Opdivo plus Yervoy had an 81% probability of remaining alive for an additional two years, compared to 72% with sunitinib; Patients who were progression-free three years after starting treatment with the dual immunotherapy combination had an 89% probability of remaining progression-free for an additional two years, compared to 57% with sunitinib. Original source: Bristol-Myers Squibb, website: http://www.bms.com/, Copyright Bristol-Myers Squibb 2021., research and development; anticancer drugs; ipilimumab; monoclonal antibodies; nivolumab; Opdivo; sunitinib malate; therapeutic antibodies; Yervoy; Bristol Myers [...]

Published
2021

38. Institute of Nanoscience and Nanotechnology Researchers Release New Data on Melanoma (Fractal and Multifractal Analysis of PET-CT Images for Therapy Assessment of Metastatic Melanoma Patients under PD-1 Inhibitors: A Feasibility Study)

Subjects
Ipilimumab -- Analysis, Metastasis -- Care and treatment, Immunotherapy -- Analysis, Nanotechnology -- Analysis, Cancer -- Care and treatment, CT imaging -- Analysis, Melanoma -- Care and treatment, Diagnostic imaging -- Analysis, Health
Abstract

2021 NOV 10 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- A new study on melanoma is now available. According to news originating from Athens, Greece, [...]

Published
2021

39. New Research on Non-Small Cell Lung Cancer from Chinese Academy of Medical Science and Peking Union Medical College Summarized (Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer)

Subjects
Oncology, Experimental -- Analysis, College costs -- Analysis, Ipilimumab -- Analysis, Lung cancer, Small cell -- Analysis, Immunotherapy -- Analysis, Medical colleges -- Analysis, Lung cancer, Non-small cell -- Analysis, Cancer -- Research, Health, Peking Union Medical College
Abstract

2021 JUL 21 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Researchers detail new data in non-small cell lung cancer. According to news reporting out of [...]

Published
2021

40. NOVEL COMBINATION SHOWS STRONG ANTITUMOR ACTIVITY IN METASTATIC RENAL CELL CARCINOMA

Author

Kahl, Kristie L.

Subjects
Ipilimumab -- Analysis, Metastasis -- Care and treatment, Carcinoma, Renal cell -- Care and treatment, Apoptosis -- Analysis, Health
Abstract

Findings from a planned interim analysis of the Ib/II Study 111 showed that lenvatinib (Lenvima) plus pembrolizumab (Keytruda) induced a disease control rate of 94% in patients with metastatic clear [...]

Published
2019

41. Researchers at University of Ghent Target Osteosarcomas (Ngs-analysis To the Rescue: Dual Checkpoint Inhibition In Metastatic Osteosarcoma ? a Case Report and Review of the Literature)

Subjects
Ipilimumab -- Analysis, Metastasis -- Prognosis, Immunotherapy -- Analysis, Osteosarcoma -- Prognosis, Chemotherapy -- Analysis, Cancer -- Chemotherapy, Health
Abstract

2021 APR 21 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- New research on Oncology - Osteosarcomas is the subject of a report. According to news [...]

Published
2021

42. Studies from University of Windsor Have Provided New Data on Melanoma (Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma)

Subjects
Skin cancer -- Care and treatment -- Prognosis, Ipilimumab -- Analysis, Metastasis -- Care and treatment -- Prognosis, Vemurafenib -- Analysis, Immunotherapy -- Analysis, Cancer -- Care and treatment -- Prognosis, Melanoma -- Care and treatment -- Prognosis, Evidence-based medicine -- Analysis, Health, University of Windsor
Abstract

2021 MAR 31 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators publish new report on melanoma. According to news reporting out of the University of [...]

Published
2021

43. Histology-independent indications in Oncology Nonclinical Models - Proof of Concept

Subjects
Ipilimumab -- Analysis, Non-Hodgkin's lymphomas -- Analysis, Animal experimentation -- Analysis, Business, international
Abstract

Amsterdam: European Medicines Agency has issued the following document: CHMP Oncology Working Party Workshop December 14, 2017 Jan Willem van der Laan Senior Pharmacology-Toxicology Assessor Chair SWP Nonclinical models for [...]

Published
2019

44. Findings in the Area of Melanoma Reported from McGill University Health Centre Research Institute (Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients)

Subjects
Cancer treatment -- Analysis, Ipilimumab -- Analysis, Nivolumab -- Analysis, Medical research -- Analysis, Immunotherapy -- Analysis, Pembrolizumab -- Analysis, Cancer metastasis -- Care and treatment, Health
Abstract

2020 SEP 16 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Researchers detail new data in Oncology - Melanoma. According to news originating from Montreal, Canada, [...]

Published
2020

45. Investigators from New York University (NYU) Langone Health Target Melanoma (Serum Interleukin-6 and C-reactive Protein Are Associated With Survival In Melanoma Patients Receiving Immune Checkpoint Inhibition)

Subjects
Ipilimumab -- Analysis, Interleukins -- Analysis, Nivolumab -- Analysis, Chemotherapy -- Analysis, C-reactive protein -- Analysis, Immunotherapy -- Analysis, Melanoma -- Patient outcomes, Cancer patients -- Patient outcomes, Health, New York University
Abstract

2020 AUG 12 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators discuss new findings in Oncology - Melanoma. According to news reporting out of New [...]

Published
2020

46. Reports on Non-Small Cell Lung Cancer from Showa University School of Medicine Provide New Insights (Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic ...)

Subjects
Ipilimumab -- Analysis, Apoptosis -- Analysis, Nivolumab -- Analysis, Small cell lung cancer -- Drug therapy, Immunotherapy -- Analysis, Pembrolizumab -- Analysis, Non-small cell lung cancer -- Drug therapy, Medical schools -- Analysis, Health
Abstract

2020 JUL 29 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators publish new report on Oncology - Non-Small Cell Lung Cancer. According to news reporting [...]

Published
2020

47. Researchers from Hebei Detail New Studies and Findings in the Area of Melanoma (Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis)

Subjects
Ipilimumab -- Analysis, Cancer -- Drug therapy, Immunotherapy -- Analysis, Pembrolizumab -- Analysis, Melanoma -- Drug therapy, Health
Abstract

2020 JUL 22 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Current study results on melanoma have been published. According to news reporting from Hebei, People's [...]

Published
2020

48. New Melanoma Study Findings Recently Were Reported by Researchers at UPMC Hillman Cancer Center (Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study)

Subjects
Ipilimumab -- Analysis, Cancer -- Care and treatment, Nivolumab -- Analysis, Cancer research -- Analysis, Immunotherapy -- Analysis, Melanoma -- Care and treatment, Cancer metastasis -- Care and treatment, Health
Abstract

2020 JUL 8 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators discuss new findings in Oncology - Melanoma. According to news reporting originating from Pittsburgh, [...]

Published
2020

49. RGENIX Highlights Biomarker and Efficacy Results from Phase 1 Dose Escalation Cohorts of RGX-104

Subjects
Ipilimumab -- Analysis, Nivolumab -- Analysis, Business, Business, international, Telecommunications industry
Abstract

RGENIX is presenting an abstract on RGX-104, RGENIX's lead therapy in development. RGENIX's abstract, 'Correlative analysis of pharmacokinetics and pharmacodynamics of RGX-104, a Liver-X-Receptor (LXR) agonist, and clinical outcomes in [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results